Sitagliptin's effects on bone tissue and osseointegration in diabetic rats

Author(s)

Gomez Bautista, Cristhian Reynaldo ^[1] ; dos Santos, Ingrid Valadares ^[1] ; Moraes, Renata Mendonca ^[1] ; Chiba, Fernando Yamamoto ^[2] ; Sumida, Doris Hissako ^[2] ; de Moraes, Michele Bianchi ^[3] ; Reis de Vasconcellos, Luana Marotta ^[1] ; Anbinder, Ana Lia ^[1]

Affiliation

^[1] Sao Paulo State Univ Unesp, Dept Biosci & Oral Diag, Inst Sci & Technol, Av Engenheiro Francisco Jose Longo 777, BR-12245000 Sao Jose Dos Campos, SP - Brazil

^[2] Sao Paulo State Univ UNESP, Sch Dent, Dept Basic Sci, Rua Jose Bonifacio 1193, BR-16015050 Aracatuba, SP - Brazil

^[3] Sao Paulo State Univ Unesp, Inst Sci & Technol, Dept Diag & Surg, Av Engenheiro Francisco Jose Longo 777, BR-12245000 Sao Jose Dos Campos, SP - Brazil

• Document type: Journal article
• Source: ARCHIVES OF ORAL BIOLOGY; v. 102, p. 238-243, JUN 2019.
• Web of Science Citations: 0

Abstract

Objective: To investigate the effects of sitagliptin, a dipeptidyl peptidase 4 inhibitor used to treat type II diabetes, on bone tissue and on implant osseointegration in diabetic rats. Design: Thirty-two male rats were divided into four groups: 1) Diabetic animals (GD); 2) Diabetic animals that received sitagliptin (GDS); 3) Normoglycemic animals (GN); and 4) Normoglycemic animals that received sitagliptin (GNS). All animals received titanium implants in the right tibia. Sitagliptin or water were administered for 4 weeks. Glycemia, HOMA-IR, insulinemia, microtomographic parameters of the left tibia and implant bone area fraction occupancy (BAFO) of the right tibia were evaluated. Results: The model used to induce diabetes led to hyperglycemia. However, HOMA-IR results showed no insulin resistance, and insulinemia was lower in diabetic animals, demonstrating the development of type I diabetes. Sitagliptin administration did not influence glycemic control. The diabetic animals showed a lower BAFO and bone volume fraction, as well as a lower trabecular number and thickness, revealing the deleterious effect of diabetes on bone metabolism and osseointegration. Conclusion: In this model, sitagliptin administration did not reverse the negative effects of type I diabetes on bone, suggesting that sitagliptin has no direct action on bone tissue and has no protective bone action in de compensated diabetic animals. (AU)

• FAPESP's process: 14/20973-6 - Effects of sitagliptin on implant osseointegration in diabetic and non-diabetic rats
• Grantee: Ingrid Valadares dos Santos
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• FAPESP's process: 17/26461-5 - Stress and periodontitis: evaluation of sympathetic innervation in the periodontium and the influence of noradrenaline on Porphyromonas gingivalis in Galleria mellonella
• Grantee: Renata Mendonça Moraes
• Support Opportunities: Scholarships in Brazil - Doctorate